Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Q4 2024 Earnings Presentation
37 slides from Omnicell's earnings presentation, Feb 6, 2025
Slide 1: Investor Presentation
Investor Presentation February 6, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Purpose and Guiding Principles
Investor Presentation – February 6, 2025 Our Purpose Our Guiding Principles To be the healthcare Our Guiding Principles represent what we providers’ most trusted stand for as a company, guiding us in every partner to enable the aspect of how we do business. Autonomous Pharmacy transformation o Passi
Slide 4: Omnicell Investment Highlights
Investor Presentation – February 6, 2025 Omnicell Investment Highlights A recognized leader in medication management with a 30-year track record and an installed base that includes more than one-half of the top 300 U.S. health systems* Investing in SaaS and Expert Services (formerly Advanced Service
Slide 5: Omnicell's Growth Strategy: Connect, Disrupt, Grow
Investor Presentation – February 6, 2025 Omnicell’s Growth Strategy is to: CONNECT the health network DISRUPT Pharmacy care with innovation GROW where care is being delivered © 2025 Omnicell, Inc. 5
Slide 6: Our Strategy
Investor Presentation – February 6, 2025 Our Strategy Omnicell is transforming pharmacy care through outcomes-centric solutions combining robotics and smart devices, software workflows, expert services, and analytics designed to optimize clinical and business outcomes across all settings of care. HE
Slide 7: The Autonomous Pharmacy
Investor Presentation – February 6, 2025 The Autonomous Pharmacy Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. o Zero medication errors o Zero medication waste o Zero human touches until delivery to patient o
Slide 8: Delivering Solutions Supporting Customer Operational and Economic Environments
Investor Presentation – February 6, 2025 Delivering Solutions Designed to Support Customer Operational and Economic Environments CHALLENGE OUTCOME DELIVERED Barcode scanning through Central 25,000 Errors Annually in Hospitals 1 100% Pharmacy robotics supports enhanced safety and accuracy 5 Reduced 5
Slide 9: Revenue Growth Drivers
Investor Presentation – February 6, 2025 Revenue Growth Drivers Deep Customer Relationships Multiple Growth and Robust Backlog Drivers o Strong position with more than o Expansion opportunities expected one-half of the top 300 U.S. health within existing customer base systems o Opportunities for pot
Slide 10: SaaS and Expert Services Recurring Revenue Growth
Investor Presentation – February 6, 2025 SaaS and Expert Services* SaaS and Expert Services Recurring Revenue Growth Potential Revenue Opportunity SaaS and Expert Services as % of Total Revenue o Leveraging established channels Targeting 23% of and strong customer relationships total revenue for 202
Slide 11: Why We Believe Omnicell is Positioned to Win
Investor Presentation – February 6, 2025 Why We Believe Omnicell is Positioned to Win Omnicell has the right Omnicell has a proven Omnicell is scaling SaaS Continued investment in solutions and the right track record of innovation and Expert Services* to new products and business model to solve as t
Slide 12: Product Overview
Product Overview
Slide 13: Points of Care
Investor Presentation – February 6, 2025 Points of Care As the final step in the pharmaceutical administration process, the bedside exchange of medication from nurse to patient is critical to care success. However, countbacks, restocks, reconciliation, and other manual tasks may force nurses to spen
Slide 14: Central Pharmacy
Investor Presentation – February 6, 2025 Central Pharmacy Central pharmacy is the medication dispensing hub of most hospitals. Roadblocks that surface here have the potential to impact patient safety, care, and clinical workflows throughout the health system. Omnicell automates manual dispensing tas
Slide 15: IV Room
Investor Presentation – February 6, 2025 IV Room Accuracy and sterility in IV compounding are paramount to patient safety, but an overreliance on 503B outsourcing and manual in-house systems often creates unnecessary risk and expense. Omnicell’s advanced automation tools including sterile compoundin
Slide 16: Specialty Pharmacy
Investor Presentation – February 6, 2025 Specialty Pharmacy As medical innovations create new, more complex drugs, many pharmacies need specialized tools and expertise to help manage the patient’s treatment journey. Opening or optimizing an in-house specialty pharmacy often requires unique capabilit
Slide 17: Ambulatory Care
Investor Presentation – February 6, 2025 Ambulatory Care Optimizing a patient’s medication journey often means extending care beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Through EnlivenHealth®, Omnicell provides patient engagement software and omnicha
Slide 18: Medication Adherence
Investor Presentation – February 6, 2025 Medication Adherence Through industry-leading packaging and automation solutions, Omnicell Medication Adherence helps to empower pharmacies to work more efficiently as they seek to and improve medication safety and effectiveness for customers and patients. Pa
Slide 19: Omnicell's Suite of SaaS and Expert Services
Investor Presentation – February 6, 2025 Omnicell’s Suite of SaaS and Expert Services* Varying combinations of robotics and smart devices, software workflows, expert services, and analytics that are designed to deliver outcomes in each setting of care where medications are managed IV Compounding Cen
Slide 20: Omnicell 2024 Innovation
Investor Presentation – February 6, 2025 Omnicell 2024 Innovation OmniSphere XT Amplify Central Med Automation Service OmniSphere April 2024 August 2024 December 2024 Innovative suite of solutions A complete solution combining Next-generation, cloud native, designed to enhance pharmacy robotics and
Slide 21: XT Amplify
Investor Presentation – February 6, 2025 XT Amplify Innovative solutions designed to maximize the value of XT technology XTExtend MedChill SupplyXpert ServerScale CarePlus © 2025 Omnicell, Inc. 21
Slide 22: Central Med Automation Service
Investor Presentation – February 6, 2025 Central Med Automation Service A powerful solution designed to ensure your pharmacy operations excel today and evolve seamlessly into the future. Robotics and Smart Devices Transforming Software Pharmacy Care Expert Services © 2025 Omnicell, Inc. 22
Slide 23: OmniSphere
Investor Presentation – February 6, 2025 OmniSphere OmniSphere is a next-generation, cloud native, software workflow engine and data platform. This groundbreaking new platform, designed to leverage the full power of a cloud native architecture, seamlessly integrates robotics and smart devices to sup
Slide 24: Fourth Quarter and Full Year 2024 Financial Highlights
Fourth Quarter and Full Year 2024 Financial Highlights
Slide 25: Financial Snapshot
Investor Presentation – February 6, 2025 Financial Snapshot Q4 ’24 YoY Change FY ’24 YoY Change Total Revenues $307 million 19% $1.112 billion (3%) Non-GAAP Gross Margin % 47.4% 380bps 44.2% (110bps) Non-GAAP Operating Expenses $113 million 9% $413 million (6%) Non-GAAP EBITDA $46 million 96% $136 m
Slide 26: New Metrics for 2025
Investor Presentation – February 6, 2025 New Metrics for 2025 o Our previous Bookings metric included Connected Devices and Software Licenses, SaaS and Expert Service* Previous Bookings Metric and Consumables. • Connected Devices and Software Licenses o For 2025, our new Product Bookings • SaaS and
Slide 27: 2024 Product Bookings and ARR Look Back
Investor Presentation – February 6, 2025 2024 Product Bookings and ARR Look Back o Our previous Bookings metric included Connected Devices and Software Licenses, SaaS and Expert Services* 2024 Bookings Using the Previous 2024 and Consumables. For 2024, Bookings Bookings Metric: $923M using the previ
Slide 28: 2025 Guidance
Investor Presentation – February 6, 2025 2025 Guidance Q1–2025 TY–2025 Long-Term Value Creation NEW: Product bookings1 Not guided $500–$550 million Opportunities NEW: ARR2 Not guided $610–$630 million o Leadership position in the digital Total Revenues $255–$265 million 1.105–1.155 billion transform
Slide 29: A Better Way: ESG in Action
Investor Presentation – February 6, 2025 A Better Way: ESG in Action 2023 Environment Social ESG Report o Decreased Scope 1 and 2 emissions in 2023 by o Amplified our charitable impact globally and almost 10% from 2022 increased employee engagement through Omnicell Published fourth annual o Strength
Slide 30: Appendix
Appendix
Slide 31: (a) For the year ended December 31, 2023, impairment charges of other assets were
(a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities. © 2025 Omnicell, Inc. 31
Slide 32: © 2025 Omnicell, Inc. (a) For the year ended December 31, 2023, impairment charges
(a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related (b) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated to property and equipment in connection with restructuring activities for op
Slide 33: (a) For the year ended December 31, 2023, impairment charges of other assets were
(a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related (b) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated to property and equipment in connection with restructuring activities for op
Slide 34: (a) For the year ended December 31, 2023, impairment charges of other assets were
(a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related (c) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based to property and equipment in connection with restructuring activities fo
Slide 35: Glossary of Terms
Investor Presentation – February 6, 2025 Glossary of Terms Bookings (Historical Metric): We utilize bookings as an indicator of the success of our business. During 2024, we defined bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and SaaS
Slide 36: Glossary of Terms Continued
Investor Presentation – February 6, 2025 Glossary of Terms Continued Product Bookings: (New Metric for 2025): We define product bookings generally as the value of non-cancelable contracts for our connected devices and software licenses. We typically exclude freight revenue and other less significant
Slide 37: Slide 37